Ambry Genetics

As a company built by scientists, genetic counselors and physicians, Ambry, a Tempus company, is your partner in #genetics and #genomics.

[Ambry Genetics @AmbryGenetics]

Join us for a webinar on Wednesday, June 3, at 10 am PDT. Marissa Russell, MS, LGC, and Gregory Nogle will explore how ordering practices impact insurance coverage. Understand the ripple effect of ordering decisions on coverage, cost, and timely care, and get real-world guidance on minimizing administrative hurdles during the genetic testing process. #GeneChat #CEUs #genetictesting #billing
https://t.co/hlP7lOgTQR

[Ambry Genetics @AmbryGenetics]

In a special Gene Scene Spotlight, Amanda Jacquart, MS, LCGC, covers MLH3. This gene is not on the ACMG Secondary Findings List, however Ambry is dedicated to the search for new, evidence-backed insights that can meaningfully impact patient care. Our latest findings include additional evidence for MLH3, which has resulted in an upgraded gene-disease validity (GDV) for autosomal recessive polyposis and colorectal cancer predisposition.
https://t.co/qhWk3k8udm

[Ambry Genetics @AmbryGenetics]

Genetic testing isn’t a one-time assessment—our understanding of DNA evolves as science advances. Ambry’s Patient for Life™ program keeps your patients’ results up to date by automatically reanalyzing eligible tests and notifying you of important changes. No retesting needed.
Learn more at https://t.co/lnQKNVpOTH
#PatientforLife #Genetics #Exome #RareDisease #VariantReclassification #AmbryGenetics

[Ambry Genetics @AmbryGenetics]

Moriah Melhado, MSPH, LCGC, explores Wilson disease associated with variants in the ATP7B gene. #GeneScene #GeneChat #exome #genetictesting
https://t.co/W1Cgll67Fg

[Ambry Genetics @AmbryGenetics]

ICYMI: Ambry was first to offer clinical concurrent RNA and DNA testing in 2019 and in 2024 we added the power of RNA to exome testing. Ambry knows there are diagnostic and clinical benefits of RNA evidence. This study acts as a proof of concept that RNA sequencing can be integrated with rare‑disease workflows and demonstrates its feasibility and informativeness when paired with exome sequencing. Dive deeper into the power of RNA: https://t.co/ou96C1Nq0x
#RNA #raredisease #exome #AmbryKnowsGenes

[Ambry Genetics @AmbryGenetics]

Why are rare diseases so hard to diagnose and how is genetic testing changing that?

Hear from Brad Power, Genomic Science Liaison Director, Rare Disease at Ambry Genetics, as we break it down and explore testing capabilities for patients still searching for answers on Doctor Radio Show on SiriusXM, Channel 110, May 20 at 6 PM ET/3 PM PT.

Listen on the SiriusXM app or online at https://t.co/nQpnl01Gab

[Ambry Genetics @AmbryGenetics]

Our latest hereditary cancer menu enhancements are now available! 

Ambry is dedicated to the search for new, evidence-backed insights that can meaningfully impact patient care. Our latest findings include additional evidence for MLH3, which has resulted in an upgraded gene-disease validity (GDV) for autosomal recessive polyposis and colorectal cancer predisposition.

This upgraded GDV–along with existing medical management guidelines–is why we’ve enhanced CancerNext®, CancerNext–Expanded®, and ColoNext® to include MLH3 in the base panels. 
https://t.co/yYop6DaMcn

[Ambry Genetics @AmbryGenetics]

Haley Streff, MS, CGC, explores ventricular arrhythmias, including catecholaminergic polymorphic ventricular tachycardia (CPVT) and calcium release deficiency syndrome (CRDS), associated with variants in the RYR2 gene. #GeneScene #GeneChat #genetictesting #Cardio https://t.co/EeiLXwZC28

[Ambry Genetics @AmbryGenetics]

Join us for a webinar on Thursday, May 21, at 11 am PDT with Allison Wong, MS, CGC, and Setareh Zandihaghighi, MS, CGC. They will explore the efficacy of implementing multiple non-traditional service delivery models in community hospital-based cancer genetic clinics and the importance of equitable identification of those at increased risk for cancer.
Register today: https://t.co/Jjx9vO2jgo
#genetictesting #GeneScene #CEUs #healthequity

[Ambry Genetics @AmbryGenetics]

What is the impact of concurrent DNA and RNA sequencing? +RNAinsight®, paired DNA/RNA testing, generates novel functional evidence that helps close data gaps and leads to a preferential improvement in accuracy among non-White populations.
Dive deeper: https://t.co/41K1bDLXlZ
#RNA #DNA #genetictesting #healthequity

[Ambry Genetics @AmbryGenetics]

While it is clear that de novo variants cause many rare genetic disorders, their detection currently requires full trio sequencing. Learn how duoNovo uses long-read sequencing to improve access to the most accurate testing for more patients by requiring only one biological parent. #genetictesting #raredisease 
https://t.co/cjBDe76rWi

[Ambry Genetics @AmbryGenetics]

In this Gene Scene, Jewel Wasson, MS, CGC, explores the SDHB gene and its association with SDHB-related Hereditary Pheochromocytoma-Paraganglioma and SDHB-related Mitochondrial Complex II Deficiency.
#GeneScene #GeneChat #genetictesting
https://t.co/x5lIKTyCMr

[Ambry Genetics @AmbryGenetics]

We’re proud to announce that the Ambry CARE Program® has been named Best Overall Health Informatics Solution in the 10th Annual MedTech Breakthrough Awards.
Selected from more than 5,000 nominations worldwide, this recognition celebrates CARE’s global impact in digital health and medical technology.
Read the press release: https://t.co/PwAG62jAn5

[Ambry Genetics @AmbryGenetics]

Today Ambry recognizes World Ovarian Cancer Day.
Early detection saves lives. If you have a history of cancer in your family, talk to your healthcare provider about genetic testing to know your risks and help inform screening and treatment options.
#WorldOvarianCancerDay #EarlyDetectionSavesLives #NoWomanLeftBehind

[Ambry Genetics @AmbryGenetics]

No clichés—just clarity. Ready to make high-risk workflows routine? Visit https://t.co/QsWrMDOUmC.

[Ambry Genetics @AmbryGenetics]

Not all classification engines are created equal. As the genomic landscape becomes more complex, the tools we use to navigate it must do more than accurately interpret, they must evolve. 🌱

Our first-ever Annual Ambry Classifi® Impact Report is here, featuring a full year of data from 2025. Merging sophisticated algorithms with clinical expertise, Classifi keeps clinics at the forefront by powering lab-driven reanalysis through our Patient for Life™ program and driving global genomic equity for the betterment of all patients.

Read the Report: https://t.co/ycFFKdGW1g

[Ambry Genetics @AmbryGenetics]

In this week's Gene Scene, Connolly Steigerwald, MS, CGC, explores the MYBP3 gene. Pathogenic variants in this gene have been associated with a spectrum of MYBPC3-related cardiomyopathies, including hypertrophic cardiomyopathy (HCM) and left ventricular noncompaction cardiomyopathy (LVNC). #GeneScene #GeneChat #Cardio
https://t.co/IGu24btHVP

[Ambry Genetics @AmbryGenetics]

We are in Washington, DC, for #ACOG2026! Visit our booth to learn more about how OB-GYNs are uniquely positioned to help patients take proactive steps toward hereditary cancer detection and what it looks like to partner with Ambry.
https://t.co/tHC7dsbduy

[Ambry Genetics @AmbryGenetics]

This Patient Experience Week, Ambry recognizes our healthcare partners who work every day to provide more answers to more patients. Heather Fecteau highlights ways The Ambry CARE Program® (CARE) helps patients make better decisions by helping them understand their options. Education is built directly into the CARE experience, designed around how patients actually learn. Dive deeper:
https://t.co/fa2zfccCJt
#CARE #genetictesting #hereditarycancer #empowered #informed

[Ambry Genetics @AmbryGenetics]

Join us for a webinar on Wednesday, May 6, at 10 am PDT/2 pm EDT. Scott Weissman, MS, CGC, will explore changes in direct-to-consumer testing and highlight practical strategies genetic counselors can use to support patients who pursue or bring results from this testing, while ensuring that consent remains meaningful and informed. #EducateNext #CEUs #GeneChat
https://t.co/D8jRGf3R45